Skip to main content

Advertisement

Log in

Analysis of cognitive dysfunction in Parkinson’s disease using voxel based morphometry and radiomics

  • Research Article
  • Published:
Cognitive Processing Aims and scope Submit manuscript

Abstract

Cognitive impairment in Parkinson’s disease (PD) is associated with changes in the brain anatomical structures. The objective of this study, is to identify the atrophy patterns based on the severity of cognitive decline and evaluate the disease progression. In this study, gray matter alterations are analysed in 135 PD subjects under 3 cognitive domains (91 Cognitively normal PD (NC-PD), 25 PD with Mild Cognitive Impairment (PD-MCI) and 19 PD with Dementia (PD-D)) by comparing them with 58 Healthy Control (HC) subjects. Voxel Based Morphometry (VBM) is used to segment the gray matter regions in magnetic resonance images and analyse the atrophy patterns statistically. Significant patterns of gray matter variations observed in the middle temporal and medial frontal region differentiate between HC and PD subject groups based on the severity of cognitive decline. Abnormalities in gray matter is substantiated through radiomic features extracted from the significant gray matter clusters. Significant radiomic features of the clusters are able to differentiate between the HC and PD-D subjects with an accuracy of 81.82%. Higher atrophy levels identified in PD-D subjects compared to NC-PD and PD-MCI group enables early diagnosis and treatment procedures. The combined and comprehensive analysis of gray matter alterations through VBM and radiomic features gives better assessment of cognitive impairment in PD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  • Aarsland D (2016) Cognitive impairment in Parkinson’s disease and dementia with Lewy bodies. Parkinsonism Relat Disord 22:144–148

    Article  Google Scholar 

  • Amoroso N, La Rocca M, Monaco A, Bellotti R, Tangaro S (2018) Complex networks reveal early MRI markers of Parkinson‟s disease. Med Image Anal 48:12–24

    Article  PubMed  Google Scholar 

  • Ashburner J, Friston KJ (2000) Voxel-based morphometry-the methods. Neuroimage 11(6):805–821

    Article  CAS  PubMed  Google Scholar 

  • Beyer MK, Janvin CC, Larsen JP, Aarsland D (2007) A magnetic resonance imaging study of patients with Parkinson’s disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry 78:254–259

    Article  PubMed  Google Scholar 

  • Bohnen NI, Muller ML, Kotagal V, Koeppe RA, Kilbourn MA, Albin RL, Frey KA (2010) Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease. Brain 133:1747–1754

    Article  PubMed  PubMed Central  Google Scholar 

  • Brooks DJ, Frey KA, Marek KL, Oakes D, Paty D, Prentice R, Shults CW, Stoessl AJ (2003) Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson’s disease. Exp Neurol 184:68–79

    Article  Google Scholar 

  • Cai D, Zhang C, He X (2010) Unsupervised feature selection for multi-cluster data. In: Proceedings of the 16th ACM SIGKDD international conference on Knowledge discovery and data mining, pp 333–342

  • Cao X, Wang X, Xue C, Zhang S, Huang Q, Liu W (2020) A radiomics approach to predicting Parkinson’s disease by incorporating whole-brain functional activity and gray matter structure. Front Neurosci 14:751

    Article  PubMed  PubMed Central  Google Scholar 

  • Cheng Z, Zhang J, He N, Li Y, Wen Y, Xu H, Tang R, Jin Z, Haacke EM, Yan F, Qian D (2019) Radiomic features of the nigrosome-1 region of the substantia nigra: using quantitative susceptibility mapping to assist the diagnosis of idiopathic Parkinson’s disease. Front Aging Neurosci 11:167

    Article  PubMed  PubMed Central  Google Scholar 

  • Chou KL, Amick MM, Brandt J, Camicioli R, Frei K, Gitelman D, Goldman J, Growdon J, Hurtig HI, Levin B, Litvan I (2010) A recommended scale for cognitive screening in clinical trials of Parkinson’s disease. Mov Disord 25(15):2501–2507

    Article  PubMed  PubMed Central  Google Scholar 

  • Cigdem O, Demirel H (2018) Performance analysis of different classification algorithms using different feature selection methods on Parkinson’s disease detection. J Neurosci Methods 309:81–90

    Article  PubMed  Google Scholar 

  • Davis AA, Racette B (2016) Parkinson disease and cognitive impairment: five new things. Neurol Clin Pract 6(5):452–458

    Article  PubMed  PubMed Central  Google Scholar 

  • Farokhian F, Beheshti I, Sone D, Matsuda H (2017) Comparing CAT12 and VBM8 for detecting brain morphological abnormalities in temporal lobe epilepsy. Front Neurol 8:428

    Article  PubMed  PubMed Central  Google Scholar 

  • Grolez G, Viard R, Lopes R, Kuchcinski G, Defebvre L, Devos D, Dujardin K, Moreau C (2020) Functional correlates of cognitive slowing in Parkinson’s disease. Parkinsonism Relat Disord 76:3–9

    Article  PubMed  Google Scholar 

  • Gul A, Perperoglou A, Khan Z, Mahmoud O, Miftahuddin M, Adler W, Lausen B (2018) Ensemble of a subset of kNN classifiers. Adv Data Anal Classif 12(4):827–840

    Article  PubMed  Google Scholar 

  • Hall JM, Lewis SJ (2019) Neural correlates of cognitive impairment in Parkinson’s disease: a review of structural MRI findings. Int Rev Neurobiol 144:1–28

    Article  PubMed  Google Scholar 

  • Halliday GM, McCann H (2010) The progression of pathology in Parkinson’s disease. Ann NY Acad Sci 1184(1):188–195

    Article  PubMed  Google Scholar 

  • Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB, Weintraub D (2009) Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 73(21):1738–1745

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hopes L, Grolez G, Moreau C, Lopes R, Ryckewaert G, Carrière N, Auger F, Laloux C, Petrault M, Devedjian JC, Bordet R (2016) Magnetic resonance imaging features of the nigrostriatal system: biomarkers of Parkinson‟s disease stages? PLoS ONE 11(4):e0147947

    Article  PubMed  PubMed Central  Google Scholar 

  • Huang H, Zheng S, Yang Z, Wu Y, Li Y, Qiu J, Cheng Y, Lin P, Lin Y, Guan J, Mikulis DJ (2023) Voxel-based morphometry and a deep learning model for the diagnosis of early Alzheimer’s disease based on cerebral gray matter changes. Cereb Cortex 33(3):754–763

    Article  PubMed  Google Scholar 

  • Li X, Xing Y, Martin-Bastida A, Piccini P, Auer DP (2018) Patterns of grey matter loss associated with motor subscores in early Parkinson’s disease. NeuroImage Clin 17:498–504

    Article  PubMed  Google Scholar 

  • Li Y, Jiang J, Lu J, Jiang J, Zhang H, Zuo C (2019) Radiomics: a novel feature extraction method for brain neuron degeneration disease using 18F-FDG PET imaging and its implementation for Alzheimer‟s disease and mild cognitive impairment. Ther Adv Neurol Disord 12:1756286419838682

    Article  PubMed  PubMed Central  Google Scholar 

  • Li L, Ji B, Zhao T, Cui X, Chen J, Wang Z (2022) The structural changes of gray matter in Parkinson disease patients with mild cognitive impairments. PLoS ONE 17(7):e0269787

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T, Coffey C, Kieburtz K, Flagg E, Chowdhury S, Poewe W (2011) The Parkinson progression marker initiative (PPMI). Prog Neurobiol 95(4):629–635

    Article  PubMed Central  Google Scholar 

  • Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53(4):695–699

    Article  PubMed  Google Scholar 

  • Nie K, Gao Y, Mei M, Guo M, Huang Z, Wang L, Zhao J, Zhang Y, Wang L (2019) The clinical characteristics and cognitive features of mild cognitive impairment in Parkinson’s disease and the analysis of relevant factors. J Clin Neurosci 63:142–148

    Article  PubMed  Google Scholar 

  • Pang H, Yu Z, Li R, Yang H, Fan G (2020) MRI-based radiomics of basal nuclei in differentiating idiopathic Parkinson’s disease from parkinsonian variants of multiple system atrophy: a susceptibility-weighted imaging study. Front Aging Neurosci 12:587250

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE (2017) Parkinson disease. Nat Rev Dis Primers 3(17013):1–21

    Google Scholar 

  • Provost JS, Hanganu A, Monchi O (2015) Neuroimaging studies of the striatum in cognition Part I: healthy individual. Front Syst Neurosci 9:140

    Article  PubMed  PubMed Central  Google Scholar 

  • Ramaniharan AK, Manoharan SC, Swaminathan R (2016) Laplace Beltrami eigen value based classification of normal and Alzheimer MR images using parametric and non-parametric classifiers. Expert Syst Appl 59:208–216

    Article  Google Scholar 

  • Rektorova I, Biundo R, Marecek R, Weis L, Aarsland D, Antonini A (2014) Grey matter changes in cognitively impaired Parkinson’s disease patients. PLoS ONE 9(1):e85595

    Article  PubMed  PubMed Central  Google Scholar 

  • Salvatore C, Cerasa A, Castiglioni I, Gallivanone F, Augimeri A, Lopez M, Arabia G, Morelli M, Gilardi MC, Quattrone A (2014) Machine learning on brain MRI data for differential diagnosis of Parkinson’s disease and progressive supranuclear palsy. J Neurosci Methods 222:230–237

    Article  CAS  PubMed  Google Scholar 

  • Sampedro F, Marín-Lahoz J, Martínez-Horta S, Pagonabarraga J, Kulisevsky J (2018) Early gray matter volume loss in MAPT H1H1 de Novo PD patients: a possible association with cognitive decline. Front Neurol 9:394

    Article  PubMed  PubMed Central  Google Scholar 

  • Siciliano M, De Micco R, Giordano A, Di Nardo F, Russo A, Caiazzo G, De Mase A, Cirillo M, Tedeschi G, Trojano L, Tessitore A (2020) Supplementary motor area functional connectivity in “drug-naïve” Parkinson’s disease patients with fatigue. J Neural Transm 127(8):1133–1142

    Article  PubMed  Google Scholar 

  • Simuni T, Caspell-Garcia C, Coffey CS, Weintraub D, Mollenhauer B, Lasch S, Tanner CM, Jennings D, Kieburtz K, Chahine LM, Marek K (2018) Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort. J Neurol Neurosurg Psychiatry 89(1):78–88

    Article  PubMed  Google Scholar 

  • Sivaranjini S, Sujatha CM (2021) Morphological analysis of subcortical structures for assessment of cognitive dysfunction in Parkinson’s disease using multi-atlas based segmentation. Cogn Neurodyn 15(5):835–845

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sun D, Wu X, Xia Y, Wu F, Geng Y, Zhong W, Zhang W, Guo D, Li C (2021) Differentiating Parkinson’s disease motor subtypes: a radiomics analysis based on deep gray nuclear lesion and white matter. Neurosci Lett 760:136083

    Article  CAS  PubMed  Google Scholar 

  • Tröster AI (2008) Neuropsychological characteristics of dementia with Lewy bodies and Parkinson’s disease with dementia: differentiation, early detection, and implications for “mild cognitive impairment” and biomarkers. Neuropsychol Rev 18:103–119

    Article  PubMed  Google Scholar 

  • Vallières M, Freeman CR, Skamene SR, El Naqa I (2015) A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities. Phys Med Biol 60(14):5471

    Article  PubMed  Google Scholar 

  • Wolters AF, Moonen AJ, Lopes R, Leentjens AF, Duits AA, Defebvre L, Delmaire C, Hofman PA, Van Bussel FC, Dujardin K (2020) Grey matter abnormalities are associated only with severe cognitive decline in early stages of Parkinson’s disease. Cortex 123:1–1

    Article  PubMed  Google Scholar 

  • Wu T, Hallett M (2013) The cerebellum in Parkinson’s disease. Brain 136(3):696–709

    Article  PubMed  PubMed Central  Google Scholar 

  • Wu Y, Jiang JH, Chen L, Lu JY, Ge JJ, Liu FT, Yu JT, Lin W, Zuo CT, Wang J (2019) Use of radiomic features and support vector machine to distinguish Parkinson’s disease cases from normal controls. Ann Transl Med 7(23):773

    Article  PubMed  PubMed Central  Google Scholar 

  • Xia J, Miu J, Ding H, Wang X, Chen H, Wang J, Wu J, Zhao J, Huang H, Tian W (2013) Changes of brain gray matter structure in Parkinson’s disease patients with dementia. Neural Regener Res 8(14):1276–1285

    Article  Google Scholar 

  • Zeng H, Cheung YM (2011) Feature selection and kernel learning for local learning-based clustering. IEEE Trans Pattern Anal Mach Intell 33(8):1532–1547

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Data used in the preparation of this article were obtained from the Parkinson’s Progression Markers Initiative (PPMI) database (www.ppmi-info.org/data). For up-to-date information on the study, visit www.ppmi-info.org. PPMI is a public-private partnership, funded by The Michael J. Fox Foundation for Parkinson’s Research and funding partners, including AbbVie, Allergan, Amathus, Avid, Biogen, BioLegend, Bristol-Myers Squibb, Celgene, Denali, GE Healthcare, Genentech, GSK, Golub Capital, Handle Therapeutics, Insitro, Janssen Neuroscience, Lilly, Lundbeck, Merck, Meso Scale Discovery, Neurocrine, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi Genzyme, Servier, Takeda, TEVA, UCB, Verily and Voyager Therapeutics (www.ppmi-info.org/fundingpartners).

Funding

No funding was received for conducting this study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S. Sivaranjini.

Ethics declarations

Conflict of interest

The authors have no competing interests to declare that are relevant to the content of this article.

Ethical approval

This study was conducted in accordance with the 1964 Declaration of Helsinki and its later amendments after approval of the local ethics committees of the sites participating to the Parkinson’s Progression Markers Initiative (PPMI). PPMI is a multicentric longitudinal study. Detailed information is available at http://ppmi-info.org/ppmiclinical-sites. The relevant local institutional review boards approved the PPMI protocol and written informed consent was obtained from all participants prior to inclusion. The approval for the use of the data in the current study was given by the Parkinson’s Progression Markers Initiative. No additional ethics approval was required from the local ethics committee where data was analysed.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Editor: Giulia Liberati (Catholic University of Louvain); Reviewers: G Venugopal (Indian Institute of Technology Madras), Sebastiano Vacca (University of Cagliari).

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sivaranjini, S., Sujatha, C.M. Analysis of cognitive dysfunction in Parkinson’s disease using voxel based morphometry and radiomics. Cogn Process (2024). https://doi.org/10.1007/s10339-024-01197-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10339-024-01197-x

Keywords

Navigation